Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres

REFERENCES

• Foster , G.R. Interferons in host defense . Semin. Liver. Dis . 1997 , 17 , 287 – 295 .
   PubMed Web of Science ®Google Scholar
• Fernandez , O. Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use? C.N.S . Drugs 2004 , 18 , 1057 – 1070 .
   Google Scholar
• Goodin , D.S. Treatment of multiple sclerosis with human beta interferon . Int. M.S. J . 2005 , 12 , 96 – 108 .
   Google Scholar
• PRISMS (Prevention or Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis) Study Group; the University of British Columbia MS/MRI Analysis Group: PRISMS-4 . Long-term efficacy of interferon-beta-1a in relapsing MS . Neurology 2001 , 56 , 1628 – 1636 .
   PubMed Web of Science ®Google Scholar
• Jacobs , L.D. ; Cookfair , D.L. ; Rudick , R.A. ; Herndon , R.M. ; Richert , J.R. ; Salazar , A.M. ; Fischer , J.S. ; Goodkin , D.E. ; Granger , C.V. ; Simon , J.H. ; Alam , J.J. ; Bartoszak , D.M. ; Bourdette , D.N. ; Braiman , J. ; Brownscheidle , C.M. ; Coats , M.E. ; Cohan , S.L. ; Dougherty , D.S. ; Kinkel , R.P. ; Mass , M.K. ; Munschauer , F.E. 3rd ; Priore , R.L. ; Pullicino , P.M. ; Scherokman , B.J. ; Whitham , R.H. ; The Multiple Sclerosis Collaborative Research Group. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann. Neurol . 1996 , 39 , 285 – 294 .
   PubMed Web of Science ®Google Scholar
• Simon , J.H. ; Jacobs , L.D. ; Campion , M. ; Wende , K. ; Simonian , N. ; Cookfair , D.L. ; Rudick , R.A. ; Herndon , R.M. ; Richert , J.R. ; Salazar , A.M. ; Alam , J.J. ; Fischer , J.S. ; Goodkin , D.E. ; Granger , C.V. ; Lajaunie , M. ; Martens-Davidson , A.L. ; Meyer , M. ; Sheeder , J. ; Choi , K. ; Scherzinger , A.L. ; Bartoszak , D.M. ; Bourdette , D.N. ; Braiman , J. ; Brownscheidle , C.M. ; Whitham , R.H. ; The Multiple Sclerosis Collaborative Research Group. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis . Ann. Neurol . 1998 , 43 , 79 – 87 .
   PubMed Web of Science ®Google Scholar
• The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999 , 53 , 679 – 686 .
   Google Scholar
• Arnason , B.G. Long-term experience with interferon beta-1b (Betaferon) in multiple sclerosis . J. Neurol . 2005 , 252 ( Suppl 3 ), iii28 – iii33 .
   Google Scholar
• Murdoch , D. ; Lyseng-Williamson , K.A. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis . Drugs 2005 , 65 , 1295 – 1312 .
   PubMed Web of Science ®Google Scholar
• Wingerchuk , D.M. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management . Expert Rev. Neurother . 2006 , 6 , 333 – 346 .
   PubMed Web of Science ®Google Scholar
• Markowitz , C. Development of interferon-beta as a therapy for multiple sclerosis . Expert Opin. Emerg. Drugs 2004 , 9 , 363 – 374 .
   PubMedGoogle Scholar
• Goodin , D.S. ; Frohman , E.M. ; Garmany , G.P. Jr. ; Halper , J. ; Likosky , W.H. ; Lublin , F.D. ; Silberberg , D.H. ; Stuart , W.H. ; van den Noort , S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines . Neurology 2002 , 58 , 169 – 178 .
   PubMed Web of Science ®Google Scholar
• Durelli , L. ; Ricci , A. Anti-interferon antibodies in multiple sclerosis. molecular basis and their impact on clinical efficacy. Front. Biosci . 2004, 9, 2192–2204.
   PubMed Web of Science ®Google Scholar
• Antonelli , G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy . Antiviral Res . 1994 , 24 , 235 – 244 .
   PubMed Web of Science ®Google Scholar
• Schellekens , H. ; Casadevall , N. Immunogenicity of recombinant human proteins: causes and consequences . J. Neurol . 2004 , 251 ( Suppl. 2 ), II4 – II9 .
   PubMedGoogle Scholar
• Bellomi , F. ; Scagnolari , C. ; Tomassini , V. ; Gasperini , C. ; Paolillo , A. ; Pozzilli , C. ; Antonelli , G. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J. Neurol. Sci . 2003 , 215 , 3 – 8 .
   PubMed Web of Science ®Google Scholar
• Schellekens , H. The immunogenicity of biopharmaceuticals . Neurology 2003 , 61 ( Suppl. 5 ), S11 – S12 .
   PubMedGoogle Scholar
• Antonelli , G. ; Bagnato , F. ; Dianzani , F. Considerations on the development of serum antibodies to interferon-beta . New Microbiol . 2005 , 28 , 183 – 192 .
   PubMed Web of Science ®Google Scholar
• Sorensen , P.S. ; Deisenhammer , F. ; Duda , P. ; Hohlfeld , R. ; Myhr , K.M. ; Palace , J. ; Polman , C. ; Pozzilli , C. ; Ross , C. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis . Eur. J. Neurol . 2005 , 12 , 817 – 827 .
   PubMed Web of Science ®Google Scholar
• Runkel , L. ; De Dios , C. ; Karpusas , M. ; Baker , D. ; Li , Z. ; Zafari , M. ; Betzenhauser , M. ; Muldowney , C. ; Miller , S. ; Redlich , P.N. ; Grossberg , S.E. ; Whitty , A. ; Hochman , P.S. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis . J. Interferon Cytokine Res . 2001 , 21 , 931 – 941 .
   PubMed Web of Science ®Google Scholar
• Deisenhammer , F. ; Reindl , M. ; Harvey , J. ; Gasse , T. ; Dilitz , E. ; Berger , T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies . Neurology 1999 , 52 , 1239 – 1243 .
   PubMed Web of Science ®Google Scholar
• Francis , G.S. ; Rice , G.P. ; Alsop , J.C. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS . Neurology 2005 , 65 , 48 – 55 .
   PubMed Web of Science ®Google Scholar
• Durelli , L. ; Verdun , E. ; Barbero , P. ; Bergui , M. ; Versino , E. ; Ghezzi , A. ; Montanari , E. ; Zaffaroni , M. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) . Lancet 2002 , 359 , 1453 – 1460 .
   PubMed Web of Science ®Google Scholar
• Giovannoni , G. ; Goodman , A. Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice? Neurology 2005 , 65 , 6 – 8 .
   PubMed Web of Science ®Google Scholar
• Perini , P. ; Facchinetti , A. ; Bulian , P. ; Massaro , A.R. ; Pascalis , D.D. ; Bertolotto , A. ; Biasi , G. ; Gallo , P. Interferon-beta (IFN-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients . Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur. Cytokine Netw . 2001 , 12 , 56 – 61 .
   Google Scholar
• Bertolotto , A. ; Deisenhammer , F. ; Gallo , P. ; Solberg Sorensen , P. Immunogenicity of interferon beta: differences among products. J. Neurol . 2004, 251 (Suppl. 2), II15–II24.
   PubMedGoogle Scholar
• WHO Expert Committee on Biological Standardization . Thirty-fifth report . World Health Organ. Tech. Rep. Ser . 1985 , 725 , 1 – 140 .
   Google Scholar
• Grossberg , S.E. ; Kawade , Y. The expression of potency of neutralizing antibodies for interferons and other cytokines . Biotherapy 1997 , 10 , 93 – 98 .
   PubMedGoogle Scholar
• Grossberg , S.E. ; Kawade , Y. ; Kohase , M. ; Yokoyama , H. ; Finter , N. The neutralization of interferons by antibody . I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J. Interferon Cytokine Res . 2001 , 21 , 729 – 742 .
   PubMed Web of Science ®Google Scholar
• Kawade , Y. Quantitation of neutralization of interferon by antibody. Meth . Enzymol . 1986 , 119 , 558 – 573 .
   Google Scholar
• Grossberg , S.E. ; Kawade , Y. ; Kohase , M. ; Klein , J.P. The neutralization of interferons by antibody. II . Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J. Interferon Cytokine Res . 2001 , 21 , 743 – 755 .
   Google Scholar
• Pungor , E. , Jr. ; Files , J.G. ; Gabe , J.D. ; Do , L.T. ; Foley , W.P. ; Gray , J.L. ; Nelson , J.W. ; Nestaas , E. ; Taylor , J.L. ; Grossberg , S.E. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b . J. Interferon Cytokine Res . 1998 , 18 , 1025 – 1030 .
   PubMed Web of Science ®Google Scholar
• Deisenhammer , F. ; Schellekens , H. ; Bertolotto , A. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis . J. Neurol. 2004 , 251 ( Suppl. 2 ), II31 – II39 .
   Google Scholar